自动化VMAT计划用于进展期胃癌术后辅助放疗
本研究针对20例进展期胃癌术后辅助放疗患者,比较全自动多准则治疗计划(autoVMAT)与专家手工VMAT计划(manVMAT)。两种计划均临床可接受,靶区覆盖相似;autoVMAT显著降低肾脏、肝脏及脊髓剂量,改善适形性和积分剂量,降低预测NTCP,但延长了治疗时间和机器跳数。
要点
- autoVMAT与manVMAT计划均临床可接受,靶区覆盖相似。
- autoVMAT显著降低双肾、肝脏中位剂量及脊髓Dmax。
- autoVMAT改善适形性和积分剂量,但治疗时间和MU增加。
核心结论
- 对于靶区形状复杂的进展期胃癌术后辅助放疗,自动化VMAT计划可行,能在不牺牲靶区剂量的前提下显著降低肾脏和肝脏剂量。
研究设计与样本
- 研究纳入20例进展期胃癌术后辅助放疗患者,为自身对照设计,比较全自动多准则治疗计划(autoVMAT)与专家手工VMAT计划(manVMAT)。
- 两种计划均采用双弧VMAT,给予PTV中位剂量45 Gy,计划与分割参数相同。
- 由两名专家放射肿瘤科医生评估临床可接受性,并行剂量体积直方图(DVH)和预测正常组织并发症概率(NTCP)分析。
主要发现
- manVMAT与autoVMAT计划均被认为临床可接受,靶区覆盖相似(manVMAT:96.6 ± 1.6%,autoVMAT:97.4 ± 1.0%,p = 0.085)。
- autoVMAT使左肾中位剂量从11.3 ± 2.1 Gy降至8.9 ± 3.5 Gy(p = 0.002),右肾从9.2 ± 2.2 Gy降至6.1 ± 1.3 Gy(p < 0.001),中位肾脏剂量平均降低>25%。
- autoVMAT使肝脏中位剂量从18.8 ± 2.3 Gy降至17.1 ± 3.6 Gy(p = 0.048),脊髓Dmax从38.3 ± 3.7 Gy降至31.6 ± 2.6 Gy(p < 0.001)。
- autoVMAT计划在剂量适形性和积分剂量上分别改善4.2%和9.1%(p < 0.001)。
- autoVMAT计划预测左肾、右肾和肝脏-PTV的NTCP分别显著降低11.3%、12.8%、7%(p ≤ 0.001)。
临床怎么用
- 对于进展期胃癌术后辅助放疗这类复杂靶区,可考虑采用自动化VMAT计划以改善肾脏、肝脏和脊髓的剂量保护。
- 采用autoVMAT时需权衡其降低OAR剂量与增加治疗时间和机器跳数之间的利弊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative/adjuvant radiotherapy of advanced gastric cancer involves a large planning target volume (PTV) with multi-concave shapes which presents a challenge for volumetric modulated arc therapy (VMAT) planning. This study investigates the advantages of automated VMAT planning for this site compared to manual VMAT planning by expert planners. METHODS: For 20 gastric cancer patients in the postoperative/adjuvant setting, dual-arc VMAT plans were generated using fully automated multi-criterial treatment planning (autoVMAT), and compared to manually generated VMAT plans (manVMAT). Both automated and manual plans were created to deliver a median dose of 45 Gy to the PTV using identical planning and segmentation parameters. Plans were evaluated by two expert radiation oncologists for clinical acceptability. AutoVMAT and manVMAT plans were also compared based on dose-volume histogram (DVH) and predicted normal tissue complication probability (NTCP) analysis. RESULTS: Both manVMAT and autoVMAT plans were considered clinically acceptable. Target coverage was similar (manVMAT: 96.6 ± 1.6%, autoVMAT: 97.4 ± 1.0%, p = 0.085). With autoVMAT, median kidney dose was reduced on average by > 25%; (for left kidney from 11.3 ± 2.1 Gy to 8.9 ± 3.5 Gy (p = 0.002); for right kidney from 9.2 ± 2.2 Gy to 6.1 ± 1.3 Gy (p < 0.001)). Median dose to the liver was lower as well (18.8 ± 2.3 Gy vs. 17.1 ± 3.6 Gy, p = 0.048). In addition, Dmax of the spinal cord was significantly reduced (38.3 ± 3.7 Gy vs. 31.6 ± 2.6 Gy, p < 0.001). Substantial improvements in dose conformity and integral dose were achieved with autoVMAT plans (4.2% and 9.1%, respectively; p < 0.001). Due to the better OAR sparing in the autoVMAT plans compared to manVMAT plans, the predicted NTCPs for the left and right kidney and the liver-PTV were significantly reduced by 11.3%, 12.8%, 7%, respectively (p ≤ 0.001). Delivery time and total number of monitor units were increased in autoVMAT plans (from 168 ± 19 s to 207 ± 26 s, p = 0.006) and (from 781 ± 168 MU to 1001 ± 134 MU, p = 0.003), respectively. CONCLUSIONS: For postoperative/adjuvant radiotherapy of advanced gastric cancer, involving a complex target shape, automated VMAT planning is feasible and can substantially reduce the dose to the kidneys and the liver, without compromising the target dose delivery.
引用
- Sharfo AWM, Stieler F, Kupfer O, et al. Automated VMAT planning for postoperative adjuvant treatment of advanced gastric cancer. Radiat Oncol. 2018. PMID: 29685166. doi:10.1186/s13014-018-1032-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。